A Review of the Clinical, Economic, and Societal Burden of Treatment-Resistant Depression: 1996–2013
The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This literature review assessed the burden of treatment-resistant depression in the United States by compiling published data about the clinical, societal, and economic outcomes associated with failure to respond to one or more adequate trials of drug therapy. METHODS: PubMed and the Tufts Cost-Effectiveness Analyses Registry were searched for English-language articles published between January 1996 and August 2013 that collected primary data about treatment-resistant depression. Two researchers independently assessed study quality and extracted data. RESULTS: Sixty-two articles were included (N=59,462 patients). Patients with treatment-resistant depression had 3.8±2.1 prior depressive episodes and illness duration of 4.4±3.3 years and had completed 4.7±2.7 unsuccessful drug trials involving 2.1±.3 drug classes. Response rates for treatment-resistant depression were 36%±1%. A total of 17%±6% of patients had prior suicide attempts (1.1±.2 attempts per patient). Quality-of-life scores (scale of 0-1, with 0 indicating death and 1 indicating perfect health) for patients with treatment-resistant depression were .41±.8 and .26±.8 points lower, respectively, than for patients who experienced remission or response. Annual costs for health care and lost productivity were $5,481 and $4,048 higher, respectively, for patients with treatment-resistant versus treatment-responsive depression. CONCLUSIONS: Treatment-resistant depression exacts a substantial toll on patients' quality of life. At current rates of 12%-20% among all depressed patients, treatment-resistant depression may present an annual added societal cost of $29-$48 billion, pushing up the total societal costs of major depression by as much as $106-$118 billion. These findings underscore the need for research on the mechanisms of depression, new therapeutic targets, existing and new treatment combinations, and tests to improve the efficacy of and adherence to treatments for treatment-resistant depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As many as 30% of patients with MDD do not adequately respond to two therapies and are considered to be treatment resistant.”
In the citing paper
“Among private payers, the mean annual direct healthcare costs per patient for the management of TRD (US$13,196; 2013 GBP8437) were higher than for management of treatment-responsive depression (US$7715; 2013 GBP4933) 14”
In the citing paper
“These cardiovascular effects may complicate treatment of patients with TRD who, in real-world settings, often have hypertension (67%) and cardiovascular disease (56%) [15].”
From Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program (2020) · cites this paper as [15]
In the citing paper
“the mean quality of life is estimated to be 20% lower in TRS compared with non-TRS. 41 Mean quality of life is approximately 25-40% lower in patients with TRD compared with patients who respond to treatment or who are in remission; 46”
From Treatment resistance in psychiatry: state of the art and new directions (2022) · cites this paper as [46]
Citations
Cites
Journal of Clinical Psychiatry
(2018) · Journal of Clinical Psychiatry · doi:10.5505/kpd · Cited by 13,651
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Childhood and adolescent depression: a review of the past 10 years, Part I
BIRMAHER, B., RYAN, N. D., WILLIAMSON, D. E., BRENT, D. A., KAUFMAN, J., DAHL, R. E., PEREL, J., & NELSON, B. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199611000-00011 · Cited by 2,076
Economic costs of diabetes in the U.S. in 2007
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-9017 · Cited by 1,323
Williams, D. R., González, H. M., Neighbors, H., Nesse, R., Abelson, J. M., Sweetman, J., & Jackson, J. S. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.3.305 · Cited by 1,293
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression
Lozano, A. M., Mayberg, H. S., Giacobbe, P., Hamani, C., Craddock, R. C., & Kennedy, S. H. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.034 · Cited by 1,024
Research works printed but not linked: 3
- Nierenberg AA, 2001, Journal of Clinical Psychiatry, 62, 5
- Thase ME, 1997, Journal of Clinical Psychiatry, 58, 23
- 1976, Clinical Global Impression (CGI)
Cited by
Items 201–300 of 576
Cabrera, L. Y., Gilbert, M. M. C., McCright, A. M., Achtyes, E. D., & Bluhm, R. L. (2021) · Psychiatric Quarterly · doi:10.1007/s11126-021-09916-9 · Cited by 30
Kanekar, S., Ettaro, R., Hoffman, M. D., Ombach, H. J., Brown, J., Lynch, C. J., Sheth, C. S., & Renshaw, P. F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158195 · Cited by 30
Kelly, M. S., Oliveira-Maia, A. J., Bernstein, M., Stern, A. P., Press, D. Z., Pascual‐Leone, Á., & Boes, A. D. (2016) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.16100181 · Cited by 23
Wu, F., Sun, H., Gong, W.-G., Li, X., Pan, Z., Shan, H., & Zhang, Z. (2020) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13450 · Cited by 21
Lipsitz, O., McIntyre, R., Rodrigues, N. B., Kaster, T., Cha, D., Brietzke, E., Gill, H., Nasri, F., Lin, K.-G., Subramaniapillai, M., et al. (2020) · Progress in Neuro-psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110126 · Cited by 22
Sun, L., Verkaik‐Schakel, R. N., Biber, K. P. H., Plösch, T., & Serchov, T. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.10.040 · Cited by 24
The complexity of treatment-resistant depression: A data-driven approach
Rost, F., Booker, T., Gonsard, A., de Felice, G., Asseburg, L., Castillo, J. M., Koutoufa, I., Ridsdale, H., Johnson, R., Taylor, D., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.04.093 · Cited by 26
“Economic ramifications further extend to increased productivity losses due to unemployment and higher dependency on state benefits (Mrazek et al., 2014).”
Obesity and Depression: A Pathophysiotoxic Relationship
Monsalve, F. A., Fernández-Tapia, B., Arriagada, O., González, D. R., & Delgado‐López, F. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311590 · Cited by 25
“One third of patients with depressive disorders are resistant to conventional treatments [87].”
Pilon, D., Sheehan, J., Szukis, H., Morrison, L., Zhdanava, M., Lefebvre, P., & Joshi, K. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.04.100 · Cited by 18
Calabrò, M., Fabbri, C., Kasper, S., Zohar, J., Souery, D., Montgomery, S., Albani, D., Forloni, G., Ferentinos, P. P., Rujescu, D., et al. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.01.008 · Cited by 19
Chan, V. K. Y., Cheung, E. C. L., Chan, S. S. M., Knapp, M. R. J., Hayes, J., Fan, M., Lai, F. T. T., Luo, H., Lum, T. Y. S., Wong, R. S. M., et al. (2022) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2022.100426 · Cited by 27
Fang, H., & Yang, Y. (2022) · Journal of Neural Engineering · doi:10.1088/1741-2552/ac7005 · Cited by 23
“Moreover, for MDD and epilepsy alone, more than 30% of the patients are treatmentresistant [14, 15], leading to an estimated annual global economic burden of over one trillion US dollars based on cost per patient-year [16, 17].”
Li, G., Bo, B., Wang, P., Qian, P., Li, M., Li, Y., Tong, C., Zhang, K., Zhang, B., Jiang, T., et al. (2023) · eLife · doi:10.7554/elife.84693 · Cited by 21
Avinun, R., Nevo, A., Knodt, A. R., Elliott, M. L., Radtke, S. R., Brigidi, B. D., & Hariri, A. R. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.1734-17.2017 · Cited by 21
“The global public health burden of depression continues to rise while effective treatment options remain limited (Mrazek et al., 2014; World Health Organization, 2017).”
BackgroundFeng, M., Crowley, N. A., Patel, A., Guo, Y., Bugni, S. E., & Luscher, B. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.03.003 · Cited by 20
“About one third of patients are treatment resistant, meaning they fail to respond to two or more currently available antidepressant drug treatments (Fava, 2003; Fava and Davidson, 1996; Mrazek et al., 2014; Thomas et al., 2013).”
BackgroundNoda, Y., Miyashita, C., Komatsu, Y., Kito, S., & Mimura, M. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2023.115573 · Cited by 22
Vieta, E., Ahmed, N., Arango, C., Cleare, A. J., Demyttenaere, K., Dold, M., Ito, T., Kambarov, Y., Krüger, S., Llorca, P., et al. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.12.013 · Cited by 23
“(Heerlein et al., 2022; Mrazek DA, 2014)”
Fornaro, M., Fusco, A., Novello, S., Mosca, P., Anastasia, A., Blasio, A. D., Iasevoli, F., & de Bartolomeis, A. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00438 · Cited by 21
Karkare, S. U., Zhdanava, M., Pilon, D., Nash, A. I., Morrison, L., Shah, A., Lefèbvre, P., & Joshi, K. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.09.005 · Cited by 22
Neurocognitive effects of subanesthetic serial ketamine infusions in treatment resistant depression
Zavaliangos‐Petropulu, A., McClintock, S. M., Khalil, J., Joshi, S. H., Taraku, B., Al‐Sharif, N., Espinoza, R. T., & Narr, K. L. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.04.015 · Cited by 27
Jamieson, C., Popova, V., Daly, E., Cooper, K., Drevets, W. C., Rozjabek, H., & Singh, J. B. (2023) · Health and Quality of Life Outcomes · doi:10.1186/s12955-023-02113-1 · Cited by 30
Peng, F., Fan, J., Ge, T., Liu, Q. Q., & Li, B. J. (2020) · Cell Proliferation · doi:10.1111/cpr.12804 · Cited by 20
Buprenorphine: prospective novel therapy for depression and PTSD
Madison, C. A., & Eitan, S. (2020) · Psychological Medicine · doi:10.1017/s0033291720000525 · Cited by 25
Clinical overview of NMDA-R antagonists and clinical practice
Davoudian, P. A., & Wilkinson, S. T. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.04.004 · Cited by 21
Madison, C. A., Kuempel, J., Albrecht, G. L., Hillbrick, L., Jayaraman, A., Safe, S. H., Chapkin, R. S., & Eitan, S. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.04.106 · Cited by 18
Liu, P., Zhang, S., Liang, Y., Gao, Z., Gao, W., & Dong, B. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s388764 · Cited by 21
Stimulation du nerf vague dans le traitement de la dépression
Senova, S., Rabu, C., Beaumont, S., Michel, V., Palfi, S., Mallet, L., & Domenech, P. (2019) · La Presse Médicale · doi:10.1016/j.lpm.2019.10.019 · Cited by 24
Effects of Baihui electroacupuncture in a rat model of depression
Mao, L., Lv, F., Yang, W.-F., Zhang, T.-F., Li, Z.-C., Li, D., & Chen, Z. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-7459 · Cited by 21
“Major depressive disorder (MDD) is associated with poor social function, low quality of life, increased economic burden, and a high risk of suicide (1).”
Youssef, N. A., Ravilla, D., Patel, C., Yassa, M., Sadek, R., Zhang, L. F., McCloud, L., McCall, W. V., & Rosenquist, P. B. (2019) · Brain Sciences · doi:10.3390/brainsci9050099 · Cited by 16
“Of those with MDE, up to a third present with treatment-resistant depression (TRD) [7,8].”
BackgroundToro-Pagán, N. M. D., Matos, A., Bardolia, C., Michaud, V., Turgeon, J., & Amin, N. S. (2022) · BMC Psychiatry · doi:10.1186/s12888-021-03659-4 · Cited by 18
Zhou, H., Zhu, J., Jia, J., Xiang, W., Peng, H., Zhang, Y., Liu, B., Mu, Y., & Lu, Y. (2022) · Neurobiology of Stress · doi:10.1016/j.ynstr.2022.100492 · Cited by 23
The prevalence and economic burden of treatment-resistant depression in Thailand
Prasartpornsirichoke, J., Pityaratstian, N., Poolvoralaks, C., Sirinimnualkul, N., Ormtavesub, T., Hiranwattana, N., Phonsit, S., & Rungnirundorn, T. (2023) · BMC Public Health · doi:10.1186/s12889-023-16477-y · Cited by 19
“Furthermore, a systematic review investigating the negative impact of TRD on health-related quality of life (HRQoL) found that on a scale of 0–1, self-rated scores were 0.26–0.41 points lower for the adult population with TRD relative to MDD in remission or those who responded to treatment [19].”
BackgroundInfluentialComputer-Assisted Cognitive Behavior Therapy to Prevent Relapse Following Electroconvulsive Therapy
Wilkinson, S. T., Ostroff, R. B., & Sanacora, G. (2017) · The Journal of ECT · doi:10.1097/yct.0000000000000348 · Cited by 17
“Treatment-resistant depression contributes substantially to the disease burden ofMDD, with increased costs of health care and productivity loss of $9529 annually compared with treatment-responsive depression.(9) Electroconvulsive therapy (ECT) is among the most effective treatment options for MDD and TRD, with respons…”
BackgroundA review of ketamine’s role in ECT and non-ECT settings
Jankauskas, V., Necyk, C., Chue, J., & Chue, P. S. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s157233 · Cited by 20
“TRD occurs at rates of 12%–20% among all depressed patients, and is associated with a disproportionately high burden of illness compared with patients who respond to treatment.(1) Ketamine is a non-barbiturate, rapid-acting general anesthetic with an onset of action within 30 s when given by intravenous (iv) injection…”
BackgroundCallegari, C., Isella, C., Caselli, I., Poloni, N., & Ielmini, M. (2019) · Journal of Personalized Medicine · doi:10.3390/jpm9020022 · Cited by 19
Magnetic seizure therapy for treatment-resistant depression
Jiang, J., Zhang, C., Li, C., Chen, Z., Cao, X., Wang, H., Li, W., & Wang, J. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013528.pub2 · Cited by 28
Najafzadeh, M., Garces, J. A., & Maciel, A. (2017) · PharmacoEconomics · doi:10.1007/s40273-017-0587-0 · Cited by 18
“We assumed that the occurrence of an ADE negatively affected a patient’s QOL [22] and we therefore penalized the QOL over that treatment period.”
BackgroundResultInfluentialGillain, B., Degraeve, G., Dreesen, T., De Bruecker, G., Buntinx, E., Beke, D., Kestens, C., Valassopoulou, E., Verhelst, F., Peeters, E., et al. (2022) · PharmacoEconomics - Open · doi:10.1007/s41669-021-00306-2 · Cited by 16
“These results are comparable to findings from a retrospective cohort study conducted in the UK [27] and international reports on quality of life and costs in function of disease severity and treatment efficacy [9, 10, 28].”
BackgroundResultInfluentialGörges, F., Oehler, C., von Hirschhausen, E., Hegerl, U., & Rummel‐Kluge, C. (2020) · Journal of Clinical Psychology · doi:10.1002/jclp.22886 · Cited by 16
Denee, T., Kerr, C., Ming, T., Wood, R., Tritton, T., Middleton-Dalby, C., Massey, O., & Desai, M. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.05.026 · Cited by 16
Ramos‐Jiménez, A., Rubio-Valles, M., Ramos-Hernández, J. A., González-Rodríguez, E., & Moreno-Brito, V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178697 · Cited by 21
“Some critical consequences of MDD and TRD include poor quality of life [3], high healthcare costs, and lost productivity, with annual expenses in the U.S. alone estimated to be between $29 billion and $48 billion [4].”
GH001 vs Placebo in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial
Cubała, W. J., Bajbouj, M., Bauer, M., Baune, B. T., Cardoner, N., Devlin, F., Doolin, K., Herrero, R. D., Elices, M., Feeney, A., et al. (2026) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2026.0096 · Cited by 20
Zhang⋆, Y., Luo, Y., Zhang, D., Pang, B., Wen, J., & Zhou, T. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.625108 · Cited by 18
Sall, S., Thompson, W., Santos, A., & Dwyer, D. S. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.698029 · Cited by 16
Ketamine: Leading us into the future for development of antidepressants
Carreno, F. R., Lodge, D. J., & Frazer, A. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112532 · Cited by 16
Saarinen, A. I. L., Hintsanen, M., Hakulinen, C. A., Pulkki-Råbäck, L., Lehtimäki, T. J., Raitakari, O. T., & Keltikangas‐Järvinen, L. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.12.045 · Cited by 20
“It has been demonstrated that among patients with clinical depression, comorbid paranoid symptoms are associated with poorer treatment outcome (Joyce et al., 2007; Mrazek et al., 2014; Skodol et al., 2011).”
Backgrounddi Michele, F., Talamo, A., Niolu, C., & Siracusano, A. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200406090051 · Cited by 16
Cano-López, J. B., Salguero, J. M., García‐Sancho, E., & Ramos‐Cejudo, J. (2020) · Journal of Psychopathology and Behavioral Assessment · doi:10.1007/s10862-020-09828-1 · Cited by 22
“It is a highly prevalent and often chronic condition (Beshai et al. 2011) and one of the most debilitating psychiatric disorders (Mrazek et al. 2014).”
BackgroundNitrous Oxide Induces Prominent Cell Proliferation in Adult Rat Hippocampal Dentate Gyrus
Chamaa, F., Bahmad, H. F., Makkawi, A.-K., Chalhoub, R., Al–Chaer, E. D., Bikhazi, G. B., Nahas, Z. H., & Abou-Kheir, W. G. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00135 · Cited by 17
“, 2005), more than 20% of patients with depression still suffer from a virulent subtype of treatment-resistant depression (TRD; Rush et al., 2006a,b; Mrazek et al., 2014).”
BackgroundAntidepressant-like activity of a brain penetrant HCN channel inhibitor in mice
Pinares-Garcia, P., Spyrou, J., McKenzie, C. E., Forster, I. C., Soh, M. S., Mohamed Syazwan, E., Atif, M., & Reid, C. A. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1159527 · Cited by 15
“As such, the exploration and development of novel antidepressant compounds with alternative mechanisms of action are essential for addressing the needs of these patients, especially when considering both the prevalence and the tremendous social, financial and health burdens of depression (Mrazek et al., 2014; Herrman…”
BackgroundYoussef, N. A., George, M. S., McCall, W. V., Sahlem, G. L., Short, B., Kerns, S., Manett, A. J., Fox, J. B., Dancy, M. M., Cook, D. N., et al. (2021) · Journal of Ect · doi:10.1097/yct.0000000000000776 · Cited by 16
Liu, H., Wang, C., Lan, X., Li, W., Zhang, F., Fu, L., Ye, Y., Ning, Y., & Zhou, Y. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1123797 · Cited by 22
“, 2006), and nearly one-third do not respond to two or more traditional antidepressant medications (McGrath et al., 2006; Mrazek et al., 2014).”
BackgroundNeurotoxins: Expanding Uses of Neuromodulators in Medicine—Major Depressive Disorder
Magid, M., Keeling, B. H., & Reichenberg, J. S. (2015) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000001733 · Cited by 18
Development of a patient decision aid for treatment resistant depression
Shillington, A. C., Langenecker, S. A., Shelton, R. C., Foxworth, P. M., Allen, L. G., Rhodes, M., Pesa, J. A., Williamson, D., & Holmes-Rovner, M. M. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.07.014 · Cited by 20
Tito, P. A. L., Bernardino, T. C. D. S., Bellozi, P. M. Q., da Silva, M. C. M., de Miranda, A. S., Vieira, É. L. M., Moreira, F. A., Palotás, A., de Oliveira, A. C. P., & Reis, H. J. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00301-8 · Cited by 16
Yu, W. S., Kwon, S., Agadagba, S. K., Chan, L.-L.-H., Wong, K.-H., & Lim, L. W. (2021) · Cells · doi:10.3390/cells10092492 · Cited by 18
Hobden, B., Schwandt, M. L., Carey, M. L., Lee, M. R., Farokhnia, M., Bouhlal, S., Oldmeadow, C. J., & Leggio, L. (2017) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13400 · Cited by 15
“The Montgomery–Asberg Depression Rating Scale (MADRS) is one of the most commonly used depression measures in research and clinical settings (Behzadifar et al., 2015; Mrazek et al., 2014).”
MethodGriffiths, C., O’Neill-Kerr, A., Millward, T., & da Silva, K. M. (2019) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2018.1562077 · Cited by 17
Jensen, K. J., Gronemann, F. H., Ankarfeldt, M. Z., Jimenez-Solem, E., Alulis, S., Riise, J., Bødker, N., Osler, M., & Petersen, J. (2022) · PLOS ONE · doi:10.1371/journal.pone.0275299 · Cited by 15
Wang, H., & Parris, J. J. (2021) · PLoS ONE · doi:10.1371/journal.pone.0255610 · Cited by 19
“For example, Mrazek and colleagues calculated the burden of major depression alone to be $106-$118 billion from 1996 to 2013 [19].”
BackgroundPharmacogenetics testing for poor response to antidepressants: a transnosographic case series
Lorvellec, M.-A., Sipahimalani, G., Lahutte, B., Delacour, H., Baldacci, A., & Saguin, E. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1440523 · Cited by 19
Yao, R., Wang, H., Yuan, M., Wang, G., & Wu, C. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.112750 · Cited by 16
Tsolaki, E. C., Narr, K. L., Espinoza, R. T., Wade, B., Hellemann, G. S., Kubicki, A., Vasavada, M. M., Njau, S. N., & Pouratian, N. (2020) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2020.05.010 · Cited by 15
Treatment resistant depression incidence and prevalence using the French nationwide claims database
Bosco‐Lévy, P., Grelaud, A., Blin, P., Astruc, B., Falissard, B., Llorca, P., Bernard, M., Lassalle, R., Moore, N. D., & Droz‐Perroteau, C. (2020) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5082 · Cited by 17
Denee, T., Ming, T., Waller, J., Bailey, T., Rajkovic-Hooley, O., Middleton-Dalby, C., Le, H. H., Zhang, Q., McCrone, P., & Taylor, D. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1857580 · Cited by 12
Ma, X., Cao, J., Zheng, H., Mei, X., Wang, M., Wang, H., Shuai, Y., & Shen, Y. (2021) · General Psychiatry · doi:10.1136/gpsych-2020-100219 · Cited by 12
Difficult-To-Treat Depression. Scoping Review.
Paganin, W., Signorini, S. G., & Sciarretta, A. (2023) · PubMed Central · doi:10.36131/cnfioritieditore20230302 · Cited by 28
“Depression is widely prevalent in Western society and ranks among the leading causes of disability worldwide (Mrazek et al., 2014).”
BackgroundSackeïm, H. A., Aaronson, S. T., Bunker, M. T., Conway, C. R., George, M. S., McAllister-Williams, H., Prudic, J., Thase, M. E., Young, A. H., & Rush, A. J. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.05.046 · Cited by 17
Tozzi, L., Anene, E. T., Gotlib, I. H., Wintermark, M., Kerr, A. B., Wu, H., Seok, D., Narr, K. L., Sheline, Y. I., Whitfield, S., et al. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.118694 · Cited by 14
Mickey, B. J., Ginsburg, Y., Jensen, E., & Maixner, D. F. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.12.028 · Cited by 14
Shang, Y., Wang, M., Hao, Q., Meng, T., Li, L., Shi, J., Yang, G., Zhang, Z., Yang, K., & Wang, J. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106031 · Cited by 14
SUMOylation and Major Depressive Disorder
Jeoung, S.-W., Park, H.-S., Ryoo, Z. Y., Cho, D., Lee, H., & Ryu, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23148023 · Cited by 15
Piccoli, E., Cerioli, M., Castiglioni, M., Larini, L., Scarpa, C., & Dell’Osso, B. M. (2022) · International Review of Psychiatry · doi:10.1080/09540261.2022.2132137 · Cited by 18
“…depression (TRD), defined as the failure to achieve remission with two or more adequate antidepressant trials (McIntyre et al., 2014), is a common clinical issue, associated with worse quality of life, loss of productivity, increased suicide risk, and poorer prognosis (Mrazek et al., 2014).”
BackgroundHuang, Y., Sun, P., Wu, Z., Guo, X., Wu, X., Chen, J., Yang, L., Wu, X., & Fang, Y. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114972 · Cited by 13
Economic evaluation of interventions for treatment-resistant depression: A systematic review
Hannah, L. A., Walsh, C., Jopling, L. A., Pérez, J. M., Cardinal, R. N., & Cameron, R. A. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1056210 · Cited by 16
NMDA Antagonists for Treatment-Resistant Depression
Farber, N. B. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_165 · Cited by 15
Vandeloo, K. L., Burhunduli, P., Bouix, S., Owsia, K., Cho, K. I. K., Fang, Z., Geel, A. V., Pasternak, O., Blier, P., & Phillips, J. L. (2022) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2022.12.007 · Cited by 18
“TRD may increase an individual’s likelihood of engaging in suicidal behaviors (2), and an estimated 30% of patients with TRD will attempt suicide in their lifetime (4).”
BackgroundKrupp, K. T., Yaeger, J. D. W., Ledesma, L. J., Withanage, M. H. H., Gale, J., Howe, C. B., Allen, T. J., Sathyanesan, M., Newton, S. S., & Summers, C. H. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109949 · Cited by 13
“Given the limitations of current antidepressant and anxiolytic medications, it is imperative that new drugs with greater efficacy and fewer side effects are tested and made available David et al. (2014).”
Kabotyanski, K. E., Najera, R. A., Banks, G. P., Sharma, H., Provenza, N. R., Hayden, B. Y., Mathew, S. J., & Sheth, S. A. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02951-7 · Cited by 13
“As DBS strategies continue to improve, so will justi fi cation for its use as an effective treatment for patients with TRD.”
BackgroundRaatikainen, I., Mäntyselkä, P. T., Vanhala, M. J., Heinonen, A. O., Koponen, H., Kautiainen, H., & Korniloff, K. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.08.039 · Cited by 13
Shrestha, A., Roach, M., Joshi, K., Sheehan, J. J., Goutam, P., Everson, K., Heerlein, K., & Jena, A. B. (2020) · Psychiatric Services · doi:10.1176/appi.ps.201900398 · Cited by 15
Marcatili, M., Sala, C., Dakanalis, A., Colmegna, F., D’Agostino, A., Gambini, O., Dell’Osso, B. M., Benatti, B., Conti, L., & Clerici, M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320968331 · Cited by 14
Desai, U. S., Kirson, N. Y., Guglielmo, A., Le, H. H., Spittle, T., Tseng-Tham, J., Shawi, M., & Sheehan, J. J. (2021) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2020-0276 · Cited by 15
Gomaa, H., Baweja, R., Mukherjee, D., He, F., Pearl, A. M., Waschbusch, D. A., Aksu, E., Liao, D., & Saunders, E. F. H. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.10.048 · Cited by 12
Zhou, Z., Chen, H., Tang, X., He, B., Gu, L., & Feng, H. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/4950414 · Cited by 12
“However, more than half of patients with severe symptoms failed to be relieved after initial treatment with antidepressant drugs [18].”
BackgroundRetractedMingardi, J., Ndoj, E., Bonifacino, T., Misztak, P., Bertoli, M., Via, L. L., Torazza, C., Russo, I., Milanese, M., Bonanno, G., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310814 · Cited by 13
Tang, Y., Chen, A., Zhu, S., Li, Y., Zhou, J., Pan, S., Shao, M., & Zhao, L.-X. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-018011 · Cited by 13
“The conventional treatment of post-stroke depression (PSD) relies on supportive therapy and medications, but a proportion of patients can remain refractory to treatment.(3) Studies have shown that repetitive transcranial magnetic stimulation (rTMS) has a definite antidepressant effect on major depression,(4) and a rec…”
BackgroundNew and emerging pharmacologic treatments for MDD
Uyar, A., & Gönül, A. S. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1621887 · Cited by 20
“The FDA approved zuranolone for PPD in 2023.”
InfluentialSalem, H., Huynh, T., Topolski, N., Mwangi, B., Trivedi, M. H., Soares, J. C., Rush, A. J., & Selvaraj, S. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.12.076 · Cited by 12
Saya, S., Chondros, P., Abela, A., Mihalopolous, C., Chatterton, M. L., Gunn, J. M., Chen, T. F., Polasek, T. M., Dettmann, E., Brooks, R., et al. (2023) · Trials · doi:10.1186/s13063-023-07361-6 · Cited by 12
“This leads to prolonged duration of symptoms, increased burden of side-effects for limited benefit and greater medical costs [9].”
BackgroundFu, J., Cai, X., Huang, S., Qiu, X., Li, Z., Hong, H., Qu, S., & Huang, Y. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.10.040 · Cited by 12
Rhee, T. G., Shim, S. R., Popp, J. H., Trikalinos, T. A., Rosenheck, R. A., Kellner, C. H., Seiner, S. J., Espinoza, R. T., Forester, B. P., & McIntyre, R. S. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02366-8 · Cited by 17
“Overall, 22 RCTs [ 39 – 60] were”
Major challenges in youth psychopathology: treatment-resistant depression. A narrative review
Menculini, G., Cinesi, G., Scopetta, F., Cardelli, M., Caramanico, G., Balducci, P. M., Giorgi, F. D., Moretti, P., & Tortorella, A. A. V. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1417977 · Cited by 20
“Indeed, TRD is associated with cognitive impairment (46), reduced coping abilities (47), and higher risk of developing medical diseases (48, 49), resulting in greater overall severity, poorer outcomes, and reduced functioning in different areas (50 – 52).”
BackgroundNikolin, S., Owens, K., Francis‐Taylor, R., Chaimani, A., Martin, D. M., Bull, M., Sackeïm, H. A., McLoughlin, D. M., Sienaert, P. A., Kellner, C. H., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-068313 · Cited by 13
Current Trends in Identifying Rapidly Acting Treatments for Depression
Ionescu, D. F., & Papakostas, G. I. (2016) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-016-0075-4 · Cited by 13
Li, Q. S., Tian, C., McIntyre, M. H., Sun, Y., Hinds, D. A., & Narayan, V. A. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.06.011 · Cited by 14
“TRD has a substantial, detrimental effect on the quality of life of affected individuals and contributes substantially to societal costs, with estimates of up to $64 billion annually in the United States (Mrazek et al., 2014)”
Voelker, J., Kuvadia, H., Cai, Q., Wang, K., Daly, E., Pesa, J. A., Connolly, N., Sheehan, J. J., & Wilkinson, S. T. (2021) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2021.100172 · Cited by 14
Lerner, D., Lavelle, T. A., Adler, D. A., Chow, W. S., Chang, H., Godar, S. C., & Rogers, W. H. (2020) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0000000000001957 · Cited by 11
Wang, T., Li, L., Yue, Y., Liu, X., Chen, S., Shen, T., Xu, Z., & Yuan, Y. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.06.042 · Cited by 10
Metadata
- Authors
- Mrazek, D. A., Hornberger, J. C., Altar, C. A., & Degtiar, I.
- Affiliations
- Mayo Clinic (US)
- Venue
- Psychiatric Services
- Published
- 2014-08
- Volume
- 65
- Issue
- 8
- Pages
- 977-987
- ISSN
- 0022-1597 (ISSN-L)
- 1075-2730
- 1557-9700
- OpenAlex
- W2111118992
- Cited by
- 580
- References
- 80
- Citations by year
- 2026: 34 · 2025: 40 · 2024: 37 · 2023: 76 · 2022: 62 · 2021: 78 · 2020: 64 · 2019: 66 · 2018: 49 · 2017: 28 · 2016: 23 · 2015: 19 · 2014: 3
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Psychiatric Services (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- treatment-resistant depression, economic burden, social burden, quality of life, health care costs, productivity loss, treatment response rate, suicide attempts, disease duration, major depressive disorder
- MeSH terms
- Major Depressive Disorder, Depressive Disorder, Major, Humans, Quality of Life, Cost of Illness, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.